Navigating the GLP-1 Medication Shortage: A Safe and Legal Alternative
As we enter the new year, the healthcare sector faces a critical challenge: the high demand for effective, but expensive, GLP-1 medications, against a backdrop of inadequate supply.
According to the FDA website, most strengths of Wegovy are in limited availability, and both Wegovy and Ozempic are currently listed as "in shortage."
This scenario has opened the door for compounded #semaglutide as a legally permissible and more affordable option. When the FDA identifies a drug shortage, compounding pharmacies are authorized to prepare doses of that drug, a regulation currently applicable to semaglutide.
These pharmacies operate under the strict oversight of State Boards of Pharmacy and must adhere to the Federal Food, Drug, and Cosmetic Act. They are required to use clinically appropriate ingredients.
At Digbi Health, we prioritize patient safety and efficacy. We advise patients considering compounded semaglutide to diligently request a certificate of analysis and analytical testing results from the compounding pharmacies. This ensures the authenticity and safety of the drug, safeguarding against counterfeit medications.
In these challenging times, exploring and utilizing all safe and legal avenues is crucial to ensure continuous and effective patient care, especially in managing conditions like #obesity . Digbi Health remains committed to guiding employers, patients, and healthcare providers through these alternatives, emphasizing both legal compliance and the highest safety standards.
#Healthcare #GLP1Shortage #PatientSafety #DigbiHealth #ObesityTreatment
President @ PrimeCare America | GCA340B
5moKeep calling them out. The proposed bill that they are supposedly sponsoring sounds like the manufs wrote it for them.